Quantcast

Latest Nycomed Stories

2010-02-04 07:01:00

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM - 11:00 AM ET at the Yale Club in New York City. Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE®...

2010-02-04 07:00:00

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 12th Annual BIO CEO & Investor Conference, to be held February 8th - 9th in New York City. Christian Itin, Ph.D., the Company's President and CEO, will present a 25 minute corporate overview on February 9th at 11:00 AM ET. The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of the...

2010-01-19 07:00:00

CUPERTINO, Calif., Jan. 19 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR(TM) (SABER(TM)-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety,...

2010-01-07 07:00:00

BETHESDA, Md., Jan. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will participate in the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11th - 14th in San Francisco. Christian Itin, Ph.D., Micromet's President and CEO, will present a 30 minute corporate overview on Thursday, January 14th at 12:30 PM PST. The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of...

2009-12-17 07:30:00

CUPERTINO, Calif., Dec. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 60 patient Phase IIb clinical trial of POSIDUR(TM), a proprietary product under development for the treatment of post-surgical pain. Top line results from this study of patients undergoing arthroscopic shoulder surgery showed a consistent reduction of pain scores (as measured by mean pain intensity on movement AUC, time normalized under the curve, during the period...

2009-09-09 02:00:00

LISBON, Portugal, September 9 /PRNewswire/ -- - Choosing a More Appropriate Route of Administration for Fast Acting Pain Relief Could be the key to Improvement The first results of the first European survey of cancer patients' experience of breakthrough pain[1] were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC). (Logo: http://www.newscom.com/cgi-bin/prnh/20090909/358726 )...

2009-08-27 17:31:00

ZURICH, Aug. 27 /PRNewswire/ -- Nycomed and Forest Laboratories today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD. COPD is an under-diagnosed progressive lung disease that may lead to death. Worldwide, COPD kills four people every minute and the World...

2009-08-10 06:00:00

NEW YORK, Aug. 10 /PRNewswire-FirstCall/ -- Forest Laboratories acquires exclusive commercialisation rights to Daxas((R)) in the United States in treatment of symptomatic COPD Nycomed to receive US$100 million upfront payment plus significant milestones and royalties Daxas filed for approval in US and Europe following encouraging results from four Phase III studies Access to Forest Laboratories' 2,700-strong US sales force completes global marketing strategy for Daxas Nycomed and...

2009-07-20 06:00:00

ZURICH, July 20 /PRNewswire/ -- Nycomed today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Daxas(R) as a once-daily oral treatment for patients with symptomatic COPD. The NDA submission is based on encouraging results from four Phase III trials of Daxas(R) (roflumilast) in the treatment of symptomatic COPD. Two pivotal 12-month studies showed positive effects on exacerbation rates and pulmonary function (FEV(1)). Two...

2009-06-18 06:00:00

BETHESDA, Md., June 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the initiation of the first clinical trial for the anti-granulocyte macrophage colony-stimulating factor (GM-CSF) human antibody MT203 by its collaboration partner Nycomed. The double-blind, randomized, placebo controlled study will investigate the safety and...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related